Cargando…
Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study
BACKGROUND: Multiple myeloma is a haematological malignancy characterized by significant morbidity and mortality. This study sought to develop an in-depth understanding of patients’ lived experiences of relapsed or refractory multiple myeloma (RRMM) and its treatment, and to identify which features...
Autores principales: | Parsons, Janet A., Greenspan, Nicole R., Baker, Natalie A., McKillop, Chris, Hicks, Lisa K., Chan, Olivia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434792/ https://www.ncbi.nlm.nih.gov/pubmed/30909874 http://dx.doi.org/10.1186/s12885-019-5467-x |
Ejemplares similares
-
Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019) -
Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020) -
Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020) -
Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010) -
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)